Royal Bank Of Canada Talaris Therapeutics, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.78 - $3.2 $3,828 - $6,883	2,151 Added 166.87%	3,440 $10,000
Q1 2023 May 15, 2023	SELL	$1.09 - $2.09 $2,528 - $4,848	-2,320 Reduced 64.28%	1,289 $2,000
Q4 2022 Feb 14, 2023	BUY	$0.94 - $1.64 $3,128 - $5,457	3,328 Added 1184.34%	3,609 $3,000
Q3 2022 Nov 14, 2022	BUY	$2.3 - $5.03 $356 - $779	155 Added 123.02%	281 $1,000
Q2 2022 Aug 15, 2022	SELL	$4.51 - $9.85 $5,339 - $11,662	-1,184 Reduced 90.38%	126 $1,000
Q1 2022 May 16, 2022	SELL	$6.89 - $16.56 $23,143 - $55,625	-3,359 Reduced 71.94%	1,310 $13,000
Q4 2021 Feb 14, 2022	BUY	$12.18 - $17.0 $45,504 - $63,512	3,736 Added 400.43%	4,669 $72,000
Q3 2021 Nov 15, 2021	BUY	$11.61 - $15.99 $3,761 - $5,180	324 Added 53.2%	933 $12,000
Q2 2021 Aug 16, 2021	BUY	$12.25 - $18.61 $7,460 - $11,333	609 New	609 $9,000

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.